Colorectal cancer remains to be a malignant and lethal disease with a poor survival rate and prognosis. The primary methods of treatment for patients with locally advanced rectal cancer (LARC), a combination of neoadjuvant chemoradiotherapy followed by total mesorectal excision is highly recommended. Neoadjuvant chemotherapy has been found to be significantly decrease local recurrence and make tumors more responsive to resection. However, the response can vary between patients and studies have highlighted approximately 15-40% of patients could obtain a pathological complete response (pCR) compared to 20% of patients who may show no side effects or symptoms following neoadjuvant chemotherapy.
Studies have demonstrated that the stage of the tumor, serum tumor markers prior to neoadjuvant therapy and lymphocyte infiltration in the tumor microenvironment (TME) influence tumor regression as a response to neoadjuvant therapy. Radiological imaging is commonly used to find predictive imaging signatures for the identification of patients who may have a good or poor response to neoadjuvant chemotherapy and therefore, can predict who may have a high risk of disease recurrence. Imaging techniques include diffusion-weighted magnetic resonance imaging (MRI), diffusion kurtosis and T2-weighted MRI and a multiparametric MRI protocol with dynamic-contrast-enhanced MRI which are used to analyze the treatment response of LARC. However, due to the sensitivity of imaging tools, more studies are required to understand how neoadjuvant chemotherapy impacts patients with localized advanced colorectal cancer.
The aim of the Research Topic is to generate a discussion on the influence of chemoradiotherapy in colorectal cancer patients and how it influences the survival rate and prognosis for patients. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Colorectal cancer remains to be a malignant and lethal disease with a poor survival rate and prognosis. The primary methods of treatment for patients with locally advanced rectal cancer (LARC), a combination of neoadjuvant chemoradiotherapy followed by total mesorectal excision is highly recommended. Neoadjuvant chemotherapy has been found to be significantly decrease local recurrence and make tumors more responsive to resection. However, the response can vary between patients and studies have highlighted approximately 15-40% of patients could obtain a pathological complete response (pCR) compared to 20% of patients who may show no side effects or symptoms following neoadjuvant chemotherapy.
Studies have demonstrated that the stage of the tumor, serum tumor markers prior to neoadjuvant therapy and lymphocyte infiltration in the tumor microenvironment (TME) influence tumor regression as a response to neoadjuvant therapy. Radiological imaging is commonly used to find predictive imaging signatures for the identification of patients who may have a good or poor response to neoadjuvant chemotherapy and therefore, can predict who may have a high risk of disease recurrence. Imaging techniques include diffusion-weighted magnetic resonance imaging (MRI), diffusion kurtosis and T2-weighted MRI and a multiparametric MRI protocol with dynamic-contrast-enhanced MRI which are used to analyze the treatment response of LARC. However, due to the sensitivity of imaging tools, more studies are required to understand how neoadjuvant chemotherapy impacts patients with localized advanced colorectal cancer.
The aim of the Research Topic is to generate a discussion on the influence of chemoradiotherapy in colorectal cancer patients and how it influences the survival rate and prognosis for patients. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
